Department of Pathology, The Ohio State University, Columbus, Ohio, USA.
J Clin Microbiol. 2012 Apr;50(4):1331-5. doi: 10.1128/JCM.06597-11. Epub 2012 Jan 25.
Clostridium difficile is the most important cause of nosocomial diarrhea. Several laboratory techniques are available to detect C. difficile toxins or the genes that encode them in fecal samples. We evaluated the Xpert C. difficile and Xpert C. difficile/Epi (Cepheid, CA) that detect the toxin B gene (tcdB) and tcdB, cdt, and a deletion in tcdC associated with the 027/NAP1/BI strain, respectively, by real-time PCR, and the Illumigene C. difficile (Meridian Bioscience, Inc.) that detects the toxin A gene (tcdA) by loop-mediated isothermal amplification in stool specimens. Toxigenic culture was used as the reference method for discrepant stool specimens. Two hundred prospective and fifty retrospective diarrheal stool specimens were tested simultaneously by the cell cytotoxin neutralization assay (CCNA) and the Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. Of the 200 prospective stools tested, 10.5% (n = 23) were determined to be positive by CCNA, 17.5% (n = 35) were determined to be positive by Illumigene C. difficile, and 21.5% (n = 43) were determined to be positive by Xpert C. difficile and Xpert C. difficile/Epi. Of the 50 retrospective stools, previously determined to be positive by CCNA, 94% (n = 47) were determined to be positive by Illumigene C. difficile and 100% (n = 50) were determined to be positive by Xpert C. difficile and Xpert C. difficile/Epi. Of the 11 discrepant results (i.e., negative by Illumigene C. difficile but positive by Xpert C. difficile and Xpert C. difficile/Epi), all were determined to be positive by the toxigenic culture. A total of 21% of the isolates were presumptively identified by the Xpert C. difficile/Epi as the 027/NAP1/BI strain. The Xpert C. difficile and Xpert C. difficile/Epi assays were the most sensitive, rapid, and easy-to use assays for the detection of toxigenic C. difficile in stool specimens.
艰难梭菌是医院获得性腹泻最重要的病因。有几种实验室技术可用于检测粪便样本中的艰难梭菌毒素或编码它们的基因。我们评估了 Xpert C. difficile 和 Xpert C. difficile/Epi(Cepheid,CA),这两种方法通过实时 PCR 分别检测毒素 B 基因(tcdB)和 tcdB、cdt 和与 027/NAP1/BI 株相关的 tcdC 缺失,Illumigene C. difficile(Meridian Bioscience,Inc.)通过粪便样本中的环介导等温扩增检测毒素 A 基因(tcdA)。毒力培养被用作粪便标本不一致时的参考方法。200 份前瞻性和 250 份回顾性腹泻粪便标本同时用细胞细胞毒素中和试验(CCNA)和 Xpert C. difficile、Xpert C. difficile/Epi 和 Illumigene C. difficile 检测。在 200 份前瞻性粪便样本中,10.5%(n=23)经 CCNA 确定为阳性,17.5%(n=35)经 Illumigene C. difficile 确定为阳性,21.5%(n=43)经 Xpert C. difficile 和 Xpert C. difficile/Epi 确定为阳性。在 50 份回顾性粪便样本中,之前经 CCNA 确定为阳性的样本中,94%(n=47)经 Illumigene C. difficile 确定为阳性,100%(n=50)经 Xpert C. difficile 和 Xpert C. difficile/Epi 确定为阳性。在 11 个不一致的结果(即,Illumigene C. difficile 阴性但 Xpert C. difficile 和 Xpert C. difficile/Epi 阳性)中,所有结果经毒力培养均确定为阳性。Xpert C. difficile/Epi 方法将 21%的分离株初步鉴定为 027/NAP1/BI 株。Xpert C. difficile 和 Xpert C. difficile/Epi 检测是最敏感、快速和易于使用的粪便标本中检测产毒艰难梭菌的方法。